このページの翻訳は実験的なもので、現在開発中です。お待ちしております

C-Rad 過去の業績

過去基準チェック /56

C-Radは、平均年間23.6%の収益成長を遂げていますが、 Medical Equipment業界の収益は、年間減少しています。収益は、平均年間5.9% 16.7%収益成長率で成長しています。 C-Radの自己資本利益率は16.6%であり、純利益率は10.5%です。

主要情報

34.4%

収益成長率

32.9%

EPS成長率

Medical Equipment 業界の成長	-9.5%
収益成長率	18.6%
株主資本利益率	17.7%
ネット・マージン	10.8%
次回の業績アップデート	23 Oct 2024

Recent updates

収支内訳

C-Rad の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

LSE:0R44 収益、費用、利益 ( )SEK Millions
日付	収益	収益	G+A経費
30 Jun 24	497	54	257
31 Mar 24	458	48	242
31 Dec 23	425	36	229
30 Sep 23	385	24	216
30 Jun 23	357	20	205
31 Mar 23	329	12	195
31 Dec 22	301	7	179
30 Sep 22	280	14	154
30 Jun 22	260	12	143
31 Mar 22	257	21	131
31 Dec 21	261	25	124
30 Sep 21	258	26	120
30 Jun 21	247	25	114
31 Mar 21	230	17	110
31 Dec 20	222	14	109
30 Sep 20	198	-11	110
30 Jun 20	201	-16	115
31 Mar 20	210	-14	120
31 Dec 19	205	-14	117
30 Sep 19	212	23	114
30 Jun 19	203	24	111
31 Mar 19	204	27	106
31 Dec 18	190	21	105
30 Sep 18	174	-2	101
30 Jun 18	161	-4	94
31 Mar 18	141	-10	91
31 Dec 17	133	-11	88
30 Sep 17	118	-16	84
30 Jun 17	108	-23	83
31 Mar 17	90	-28	80
31 Dec 16	83	-31	75
30 Sep 16	74	-33	71
30 Jun 16	70	-32	67
31 Mar 16	73	-27	62
31 Dec 15	73	-21	58
30 Sep 15	73	-20	57
30 Jun 15	66	-16	52
31 Mar 15	62	-8	50
31 Dec 14	57	-7	47
30 Sep 14	56	-5	45
30 Jun 14	59	-4	44
31 Mar 14	52	-17	44
31 Dec 13	49	-21	44
30 Sep 13	43	-20	39

質の高い収益: 0R44は高品質の収益を持っています。

利益率の向上: 0R44の現在の純利益率 (10.8%)は、昨年(5.7%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 0R44の収益は過去 5 年間で年間34.4%増加しました。

成長の加速: 0R44の過去 1 年間の収益成長率 ( 164% ) は、5 年間の平均 ( 年間34.4%を上回っています。

収益対業界: 0R44の過去 1 年間の収益成長率 ( 164% ) はMedical Equipment業界39.9%を上回りました。

株主資本利益率

高いROE: 0R44の自己資本利益率 ( 16.6% ) は低いとみなされます。

C-Rad 過去の業績

過去 基準チェック /56

主要情報

最近の業績更新

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.16 in 2Q 2023)

Full year 2023 earnings released: EPS: kr1.05 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: kr1.36 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Third quarter 2023 earnings released

Recent updates

CEO & President recently bought kr85k worth of stock

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.16 in 2Q 2023)

Full year 2023 earnings released: EPS: kr1.05 (vs kr0.22 in FY 2022)

C-Rad AB (publ) Appoints Mats Thorén as Board Member

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: kr1.36 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings released

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

C-Rad AB (publ) Announces CFO Changes

C-Rad AB (publ) to Report Q3, 2023 Results on Oct 27, 2023

C-RAD Launches New Updated eDucation Portal as an Online Platform

Second quarter 2022 earnings released

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Insufficient new directors

Insufficient new directors

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

C-Rad and With-Global Engages in a Partnership for the South Korean Market

C-RAD Receives Order for Proton Cancer Treatment Centers in the US

Shenzhen Proton Therapy Treatment Center Selects C-Rad Catalyst™ System

C-Rad AB (publ) to Report Q2, 2021 Results on Jul 29, 2021

Shanghai Proton and Heavy Ion Hospital Decides for C-Rad Sigrt Solution

Australian Customers Select C-RAD’s Cutting Edge SIGRT Solution

C-Rad AB Receives SEK 11 Million Order for Cutting Edge SIGRT Solution by DTZ in Berlin

Independent Director recently sold kr672.4k worth of stock

Independent Director recently bought kr1.7m worth of stock

Independent Director recently sold kr3.4m worth of stock

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /56